Treatment with the Biscoclaurine Alkaloid Cepharanthine Significantly Increases Salivary Secretion in Primary Sjögren's Syndrome Patients

• 資料種別: 博士論文
• タイトル: Treatment with the Biscoclaurine Alkaloid Cepharanthine Significantly Increases Salivary Secretion in Primary Sjögren's Syndrome Patients
• 著者・編者: Yamanoi, Tomoko; Aota, Keiko; Momota, Yukihiro; Azuma, Masayuki
• 著者標目: Yamanoi, Tomoko; Aota, Keiko; Momota, Yukihiro; Azuma, Masayuki
• 出版事項: 四国歯学会
• 出版年月日等: 2017-04-04
• 出版年（W3CDTF）: 2017-04-04
• 並列タイトル等: ビスコクラウリン型アルカロイドであるセファランチンは、1次性シェーグレン症候群患者の唾液分泌量を著明に増加させる
• タイトル（掲載誌）: Journal of Oral Health and Biosciences
• 巻号年月日等（掲載誌）: 29 2
• 掲載巻: 29
• 掲載号: 2
• 掲載ページ: 39-48
• ISSN（掲載誌）: ISSN : 2189-6682; ISSN : 2188-7888
• 授与機関名: 徳島大学
• 授与年月日: 2017-03-23
• 報告番号: 甲第3070号
• 学位: 博士（歯学）
• 本文の言語コード: eng
• 件名標目: Primary Sjögren's syndrome; NF-κB; MMP-9; Type IV collagen; Acinar structure; salivary gland; sjögren's syndrome; salivary secretion; cepharanthin
• 対象利用者: 一般
• 一般注記: Objective: Our previous findings suggested that the suppression of tumor necrosis factoralpha (TNF-α)-induced matrix metalloproteinase (MMP)-9 production by the biscoclaurine alkaloid cepharanthine could prevent the destruction of the acinar structure in the salivary glands of murine Sjögren's syndrome. Here, we examined the effect of cepharanthine on the salivary secretion in primary Sjögren's syndrome (pSS) patients. Methods: In this single-center, open-label pilot study, 29 patients with pSS (28 women, 1 man) received 6 mg/day orally cepharanthine for 12 months. Standard clinical assessments and stimulated salivary flow were examined at baseline and each month for 12 months in all 29 patients. In eight of the patients, inflammatory lesions in the salivary glands were histologically investigated before and after the cepharanthine treatment. We analyzed the expressions of p65, phosphorylated IκB-α, MMP-9, and type IV collagen immunohistochemically. Results: All patients completed the study without any adverse events. A significant increase in salivary flow was observed after the cepharanthine treatment compared to baseline. The serological analysis revealed that the 14 patients with an anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro) antibody value that was either negative or <64 U/ml responded significantly well to this treatment, whereas the 15 patients with anti-SSA/Ro antibody values >64 U/ml did not. The immunohistochemical analysis demonstrated that although p65, phosphorylated IκB-α, and MMP-9 were more strongly stained in the acinar cells of the patients at baseline compared to the staining at the completion of cepharanthine treatment, the continuity of type IV collagen was observed following the cepharanthine treatment. These results indicate that cepharanthine could inhibit the phosphorylation of IκB-α, followed by the prevention of MMP-9 activation and the stabilization of type IV collagen. Conclusions: Our findings suggest that cepharanthine could be a promising agent for improving salivary secretion in pSS patients.
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.20738/johb.29.2_39
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/111058/20190820160914154468/LID201704251010.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/111058/20190820160914651517/LID201704251011.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/111058/20190820160915163773/LID201704251012.pdf fulltext